Theravance Biopharma (TBPH) Non-Current Assets (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Non-Current Assets data on file, last reported at $54.7 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $54.7 million, down 71.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $242.3 million (down 72.11% YoY), and the FY2025 annual result was $67.1 million, down 65.24% from the prior year.
• Non-Current Assets retreated to $54.7 million in Q1 2026 per TBPH's latest filing, from $67.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $277.2 million in Q1 2023 and troughed at $54.7 million in Q1 2026.
• A 5-year average of $191.3 million and a median of $239.6 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 573.66% in 2022, then plunged 75.39% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $253.9 million in 2022, then fell by 2.16% to $248.5 million in 2023, then retreated by 22.28% to $193.1 million in 2024, then plunged by 65.24% to $67.1 million in 2025, then decreased by 18.52% to $54.7 million in 2026.
• Business Quant data shows TBPH's Non-Current Assets at $54.7 million in Q1 2026, $67.1 million in Q4 2025, and $60.8 million in Q3 2025.